Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

Conditions: Advanced Renal Cell Carcinoma (aRCC) Interventions: Combination Product: Nivolumab + Ipilimumab combination therapy; Combination Product: Pembrolizumab + Lenvatinib combination therapy Sponsors: Bristol-Myers Squibb Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials